PTPRT and head and neck squamous cell carcinoma: Similarly, high expression of PTPRT was also significantly correlated with favourable prognosis of patients with LUSC (HR = 0.7, 95% CI 0.52 ~ 0.95, P = 0.02; Fig. 6B), breast carcinoma (HR = 0.44, 95% CI 0.29 ~ 0.65, P = 3.9E-5; Fig. 6C), head and neck squamous cell carcinoma (HNSCC, HR = 0.73, 95% CI 0.55 ~ 0.97, P = 0.029; Fig. 6D), pancreatic adenocarcinoma (PAAD, H = 0.38, 95% CI 0.25 ~ 0.59, P = 6E-6; Fig. 6E), and rectum adenocarcinoma (READ, HR = 0.36, 95% CI 0.16 ~ 0.8, P = 0.0094; Fig. 6F).